Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phenylbutyrate for Alpha-Synuclein Clearance in Parkinson's
NCT02046434Phase 1Completed
- Sponsor
- University of Colorado Denver
- Start
- Jan 2014
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of glycerol phenylbutyrate in Parkinson's disease (PD) (2 arms), sponsored by University of Colorado Denver. Primary endpoint: Levels of alpha-synuclein in blood plasma at Day 28. Started Jan 2014; status: completed.
02
Drugs
glycerol phenylbutyrate
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02046434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02046434.